Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jul 03, 2023 12:56pm
397 Views
Post# 35524908

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Eli Lilly buys Sigilon for US$126ps which traded at $0.33ps

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Eli Lilly buys Sigilon for US$126ps which traded at $0.33ps Being above $3 Nas is one thing. Closing above $3 is a recently new indicator.
with 15 min to go, the Nas price is again gaining strength.
A clear sign we/ I have not seen in a long time.
Anyone following does know " news within 90 days" now 80 days, regarding a phase 3 entry & most likely a partership.
So yes something is going on.
want some good returns, buy, hold & wait.
80 days , not that far off.
they did say " within".
lots of comparables in the biotech industry to add to Onc s negotiating pool.
id say we will see $15ps CDN , before end of October.
A phase 3 entry ( they have 2 ready to go), with Roche for example, will. Validate present  & future strength of the compnay.
Well above $15 ps. ....I'm being conservative.
some will say " same old thing, we have seen this before", pump & dump etc.
again, the late day trading & support is not " the same old thing"
two phase 3 ready options, not the same old thing
day traders WILL come & go.
however, there has been some serious support last few weeks.

<< Previous
Bullboard Posts
Next >>